3-(3,5-Dimethoxyphenyl)-2-[4-(4-formylphenoxy)-phenyl]-acrylic acid methyl ester | 380881-29-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3-(3,5-Dimethoxyphenyl)-2-[4-(4-formylphenoxy)-phenyl]-acrylic acid methyl ester
• 英文别名: methyl 3-(3,5-dimethoxyphenyl)-2-[4-(4-formylphenoxy)phenyl]prop-2-enoate
• CAS: 380881-29-8
• 化学式: C₂₅H₂₂O₆
• 分子量: 418.446
• InChiKey: LABIBXSBNOZRJG-UHFFFAOYSA-N

物化性质

• 沸点：
  583.4±50.0 °C(Predicted)
• 密度：
  1.220±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  71.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(3,5-Dimethoxyphenyl)-2-[4-(4-formylphenoxy)-phenyl]-acrylic acid methyl ester 在 sodium borohydrid 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 以100%的产率得到3-(3,5-Dimethoxyphenyl)-2[4-(4-hydroxymethylphenoxy)-phenyl]-acrylic acid methyl ester
  参考文献：
  名称：

  Novel heterocyclic analogs of diphenylethylene compounds

  摘要：

  提供含有噻唑二酮或噁唑二酮基团的新型二苯乙烯化合物及其衍生物，对II型糖尿病动物模型中的降低血糖水平、血清胰岛素、甘油三酯和游离脂肪酸水平具有有效作用。这些化合物被披露为用于多种治疗，包括治疗炎症、炎症和免疫性疾病、胰岛素抵抗、高脂血症、冠状动脉疾病、癌症和多发性硬化等。

  公开号：

  US20030181494A1
• 作为产物：
  描述：

  2-(4-hydroxyphenyl)-3-(3,5-dimethoxyphenyl)acrylic acid methyl ester 、 sodium;hydride 、 对氟苯甲醛 在 氩 、 水 、 Sodium sulfate-III 作用下， 以 N,N-二甲基甲酰胺 、 乙酸乙酯 为溶剂， 反应 34.0h， 以to yield 9 as pale yellow, solid (445 g, 77%)的产率得到3-(3,5-Dimethoxyphenyl)-2-[4-(4-formylphenoxy)-phenyl]-acrylic acid methyl ester
  参考文献：
  名称：

  Heterocyclic analogs of diphenylethylene compounds

  摘要：

  提供一种含有噻唑烷二酮或肟唑烷二酮基团的新型二苯乙烯化合物及其衍生物，对于2型糖尿病动物模型具有降低血糖水平、血清胰岛素、三酰甘油和游离脂肪酸水平的有效性。这些化合物可用于多种治疗，包括炎症、炎症和免疫性疾病、胰岛素抵抗、高脂血症、冠状动脉疾病、癌症和多发性硬化的治疗。

  公开号：

  US07407978B2

文献信息

• Compounds for treatment of inflammation, diabetes and related disorders
  申请人：——

  公开号：US20040097593A1

  公开（公告）日：2004-05-20

  Novel acyl urea, thiourea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction in an animal model of arthritis and in lowering blood glucose levels in animal models of Type II diabetes mellitus. The compounds are disclosed as useful for a variety of treatments including the treatment of diabetes mellitus, insulin resistance, inflammation, inflammatory diseases, immunological diseases and cancer.

  提供了一系列新型酰基脲、硫脲、氨基甲酸酯、硫代氨基甲酸酯及相关化合物，这些化合物在培养细胞中抑制细胞因子介导的炎症反应、改善动物关节炎模型中的骨破坏以及降低动物2型糖尿病模型中的血糖水平方面具有有效性。这些化合物可用于多种治疗，包括糖尿病、胰岛素抵抗、炎症、炎症性疾病、免疫疾病和癌症的治疗。
• Novel Heterocyclic analogs of diphenylethylene compounds
  申请人：——

  公开号：US20020025975A1

  公开（公告）日：2002-02-28

  Novel diphenylethylene compounds containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

  本发明提供了含有噻唑烷二酮或噁唑烷二酮基团的新型二苯乙烯化合物，可有效降低2型糖尿病动物模型中的血糖水平、血清胰岛素、甘油三酯和游离脂肪酸水平。与以往报道的降低瘦素水平的噻唑烷二酮化合物相比，本化合物可增加瘦素水平且无已知的肝毒性。该化合物被揭示为用于多种治疗，包括治疗炎症、炎症和免疫性疾病、胰岛素抵抗、高脂血症、冠状动脉疾病、癌症和多发性硬化症。
• COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS
  申请人：Neogi Partha

  公开号：US20070259961A9

  公开（公告）日：2007-11-08

  Novel acyl urea, thiourea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction in an animal model of arthritis and in lowering blood glucose levels in animal models of Type II diabetes mellitus. The compounds are disclosed as useful for a variety of treatments including the treatment of diabetes mellitus, insulin resistance, inflammation, inflammatory diseases, immunological diseases and cancer.

  提供了一系列新型酰基脲、硫脲、氨基甲酸酯、硫代氨基甲酸酯及相关化合物，这些化合物在培养细胞中抑制细胞因子介导的炎症反应、改善关节炎动物模型中的骨破坏和降低2型糖尿病动物模型中的血糖水平方面具有有效性。这些化合物被披露为用于多种治疗，包括糖尿病、胰岛素抵抗、炎症、炎症性疾病、免疫疾病和癌症的治疗。
• Novel heterocyclic analogs of diphenylethylene compounds
  申请人：——

  公开号：US20030181494A1

  公开（公告）日：2003-09-25

  Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

  提供含有噻唑二酮或噁唑二酮基团的新型二苯乙烯化合物及其衍生物，对II型糖尿病动物模型中的降低血糖水平、血清胰岛素、甘油三酯和游离脂肪酸水平具有有效作用。这些化合物被披露为用于多种治疗，包括治疗炎症、炎症和免疫性疾病、胰岛素抵抗、高脂血症、冠状动脉疾病、癌症和多发性硬化等。
• Heterocyclic analogs of diphenylethylene compounds
  申请人：Theracos, Inc.

  公开号：US07202366B2

  公开（公告）日：2007-04-10

  Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

  本发明提供了含有噻唑烷二酮或噁唑烷二酮基团的新型二苯乙烯化合物及其衍生物，对于二型糖尿病动物模型中的降低血糖、血清胰岛素、甘油三酯和游离脂肪酸水平非常有效。与先前报道的降低瘦素水平的噻唑烷二酮化合物相比，本发明的化合物增加了瘦素水平，并且没有已知的肝毒性。这些化合物被披露为用于各种治疗，包括治疗炎症、炎症和免疫性疾病、胰岛素抵抗、高血脂症、冠状动脉疾病、癌症和多发性硬化症。